The effects of beta-arrestin1 deletion on acute cannabinoid activity, brain cannabinoid receptors and tolerance to cannabinoids in mice

References

• Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646–7
   Web of Science ®Google Scholar
• Devane WA, Dysarz FA, III Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605–13
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240–4
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–4
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61–5
   PubMed Web of Science ®Google Scholar
• Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994;268:1612–23
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 1998;5:417–31
   PubMed Web of Science ®Google Scholar
• Prather PL, Martin NA, Breivogel CS, Childers SR. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol Pharmacol 2000;57:1000–10
   PubMed Web of Science ®Google Scholar
• Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996;91:1585–614
   PubMed Web of Science ®Google Scholar
• Heyser CJ, Hampson RE, Deadwyler SA. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 1993;264:294–307
   PubMed Web of Science ®Google Scholar
• Fan F, Compton DR, Ward S, et al. Development of cross-tolerance between Δ9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 1994;271:1383–90
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Stevenson LA, Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 1993;110:1483–90
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Childers SR, Deadwyler SA, et al. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 1999;73:2447–59
   PubMed Web of Science ®Google Scholar
• Rubino T, Vigano D, Massi P, Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 2000;75:2080–6
   PubMed Web of Science ®Google Scholar
• Jeffery DR, Charlton RR, Venter JC. Reconstitution of turkey erythrocyte beta-adrenergic receptors into human erythrocyte acceptor membranes. Demonstration of guanine nucleotide regulation of agonist affinity. J Biol Chem 1980;255:5015–18
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Childers SR. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 2000;295:328–36
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Puri V, Lambert JM, et al. The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain. J Recept Signal Transduct Res 2013;33:367–79
   PubMed Web of Science ®Google Scholar
• Lefkowitz RJ, Inglese J, Koch WJ, et al. G-protein-coupled receptors: regulatory role of receptor kinases and arrestin proteins. Cold Spring Harb Symp Quant Biol 1992;57:127–33
   PubMedGoogle Scholar
• Attramadal H, Arriza JL, Aoki C, et al. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 1992;267:17882–90
   PubMed Web of Science ®Google Scholar
• Lefkowitz RJ. Arrestins come of age: a personal historical perspective. Prog Mol Biol Transl Sci 2013;118:3–18
   PubMed Web of Science ®Google Scholar
• Ma L, Pei G. Beta-arrestin signaling and regulation of transcription. J Cell Sci 2007;120:213–18
   PubMed Web of Science ®Google Scholar
• DeFea KA, Vaughn ZD, O'Bryan EM, et al. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 2000;97:11086–91
   PubMed Web of Science ®Google Scholar
• Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA 2001;98:2449–54
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Lambert JM, Gerfin S, et al. Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 −/− mice. Behav Pharmacol 2008;19:298–307
   PubMed Web of Science ®Google Scholar
• Bohn LM, Dykstra LA, Lefkowitz RJ, et al. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 2004;66:106–12
   PubMed Web of Science ®Google Scholar
• Nguyen PT, Schmid CL, Raehal KM, et al. Beta-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry 2012;71:714–24
   PubMed Web of Science ®Google Scholar
• Conner DA, Mathier MA, Mortensen RM, et al. Beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ Res 1997;81:1021–6
   PubMed Web of Science ®Google Scholar
• Gainetdinov RR, Premont RT, Bohn LM, et al. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004;27:107–44
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Baghar AM, Kelly MEM, et al. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem 2014;289:24845–62
   PubMed Web of Science ®Google Scholar
• Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin2 knockout mice. J Pharmacol Exp Ther 2005;314:1195–201
   PubMed Web of Science ®Google Scholar
• Winters WD, Hance AJ, Cadd GG, et al. Ketamine- and morphine-induced analgesia and catalepsy. I. Tolerance, cross-tolerance, potentiation, residual morphine levels and naloxone action in the rat. J Pharmacol Exp Ther 1988;244:51–7
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54
   PubMed Web of Science ®Google Scholar
• Moore RJ, Xiao R, Sim-Selley LJ, Childers SR. Agonist-stimulated [35S]GTPgammaS binding in brain: modulation by endogenous adenosine. Neuropharmacology 2000;39:282–9
   PubMed Web of Science ®Google Scholar
• Bohn LM, Gainetdinov RR, Lin FT, et al. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000;408:720–3
   PubMed Web of Science ®Google Scholar
• Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999;283:401–4
   PubMed Web of Science ®Google Scholar
• Sain NM, Liang A, Kane SA, Urban MO. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(−/−) and not CB2(−/−) mice in models of acute and persistent pain. Neuropharmacology 2009;57:235–41
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001;60:155–63
   PubMed Web of Science ®Google Scholar
• Strachan RT, Sun JP, Rominger DH, et al. Divergent transducer-specific molecular efficacies generate biased agonism at a G-protein-coupled receptor (GPCR). J Biol Chem 2014;289:14211–24
   PubMed Web of Science ®Google Scholar
• Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007;28:416–22
   PubMed Web of Science ®Google Scholar